MOGAMULIZUMAB

Brand name:

• Poteligeo®

Form and strength:

Please search for and view the medicine's Public Summary Document (PSD) for more information

Submission sponsor:

KYOWA KIRIN AUSTRALIA PTY LTD

Condition/indication:
(therapeutic use)

• Cutaneous T-cell lymphoma (CTCL)

Listing requested:

Please see PSD for more information

Funding program:

Please see PSD for more information

Request authority level:

Please see PSD for more information

PBAC Submission type:

New PBS listing (Standard Re-entry Pathway)

Comment:

--

Other PBAC consideration:

• MOGAMULIZUMAB
• MOGAMULIZUMAB

Submission received for:

March 2025 PBAC meeting

Opportunity for consumer comment:

Open 27/11/2024 and close 29/01/2025 (see PBS Website)

PBAC meeting:

Held on 12/03/2025

PBAC outcome published:

Recommended (see PBAC Outcomes)

Notice of intent submitted:

13/10/2025

Lodgement of required documentation:

13/11/2025

Acceptance of complete documentation:

Accepted

Agreement to listing arrangements:

Commenced on 10/12/2025

Status:

Finalised

7Government processes:

Commenced on 17/12/2025

8Medicine listed on the PBS:

Has not yet occurred